Tac2-N Serves an Oncogenic Role and Promotes Drug Resistance in Human Gastric Cancer Cells

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2020 Sep 29

PMID 32989391

Citations 3

Authors

Lei Shen

Pingping Zhang

Jianbing Wang

Peng Ji

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is one of the most common types of malignancy worldwide. Tac2-N (TC2N) has been reported to serve as either an oncogene or tumor suppressor in numerous different types of cancer; however, the role of TC2N in gastric cancer remains poorly understood. The present study aimed to investigate the role of TC2N in gastric cancer and reveal its regulatory mechanism. A Cell Counting Kit-8 assay was used to analyze the cell proliferation rate, while wound healing and Transwell Matrigel assays were performed to determine the cell migratory and invasive abilities, respectively. Cell cycle distribution was determined by flow cytometric analysis, and the expression levels of TC2N, P-glycoprotein (P-gp), cyclin D1, CDK4, cyclin E1, MMP2, MMP9 and N-Myc downstream regulated gene 1 were analyzed using reverse transcription-quantitative PCR or western blotting. Bioinformatics analysis revealed a high expression of TC2N in patients with gastric cancer. The experimental results revealed that TC2N expression levels were significantly unregulated in gastric cancer cell lines. The knockdown of TC2N in AGS cells significantly inhibited the cell proliferation rate and induced cell cycle arrest at the G0/G1 phase, while downregulating cyclin E1, cyclin D1 and CDK4 expression levels. The knockdown of TC2N also inhibited cell migration and invasion. Furthermore, the knockdown of TC2N improved the sensitivity of AGS cells to cisplatin, paclitaxel and 5-fluorouracil, and downregulated the protein expression levels of P-gp. By contrast, TC2N overexpression exerted the opposite effects in AGS cells. In conclusion, the findings of the present study indicated that the genetic knockdown of TC2N may inhibit cell proliferation, migration and invasion, while inducing cell cycle arrest in the G1/S phase and reversing the drug resistance of AGS cells, which may be partly through inhibiting P-gp expression levels. Thus, TC2N may serve as a novel diagnostic marker and therapeutic target for patients with gastric cancer.

Citing Articles

TC2N maintains stem cell-like characteristics to accelerate lung carcinogenesis by blockade of dual specificity protein phosphatase 3.

Gu J, Lv Y, Xia J, Bai F, Gong J, Pan G Cell Biosci. 2025; 15(1):8.

PMID: 39849581 PMC: 11758731. DOI: 10.1186/s13578-025-01348-3.

An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives.

Zhang H, Li Y, Liu Y Front Pharmacol. 2024; 15:1374264.

PMID: 38962311 PMC: 11220241. DOI: 10.3389/fphar.2024.1374264.

TC2N inhibits distant metastasis and stemness of breast cancer via blocking fatty acid synthesis.

Hao X, Lv Y, Li D, Bai F, Gong J, Pan G J Transl Med. 2024; 22(1):6.

PMID: 38167440 PMC: 10763294. DOI: 10.1186/s12967-023-04721-3.

TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.

Li H, Fang H, Chang L, Qiu S, Ren X, Cao L Front Immunol. 2021; 12:764749.

PMID: 34925334 PMC: 8674203. DOI: 10.3389/fimmu.2021.764749.

References

Yang Q, Zhu C, Zhang Y, Wang Y, Wang Y, Zhu L . Molecular analysis of gastric cancer identifies genomic markers of drug sensitivity in Asian gastric cancer. J Cancer. 2018; 9(16):2973-2980. PMC: 6096361. DOI: 10.7150/jca.25506. View

Galderisi U, Jori F, Giordano A . Cell cycle regulation and neural differentiation. Oncogene. 2003; 22(33):5208-19. DOI: 10.1038/sj.onc.1206558. View

Kabekkodu S, Bhat S, Radhakrishnan R, Aithal A, Mascarenhas R, Pandey D . DNA promoter methylation-dependent transcription of the double C2-like domain β (DOC2B) gene regulates tumor growth in human cervical cancer. J Biol Chem. 2014; 289(15):10637-10649. PMC: 4036182. DOI: 10.1074/jbc.M113.491506. View

Liu W, Hua S, Dai Y, Yuan Y, Yang J, Deng J . Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase. Int J Clin Exp Pathol. 2016; 8(11):14315-24. PMC: 4713533. View

Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F . Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014; 50(7):1330-44. DOI: 10.1016/j.ejca.2014.01.029. View

Hao X, Gao L, Deng X, Han F, Chen H, Jiang X . Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell Death Dis. 2019; 10(6):424. PMC: 6541591. DOI: 10.1038/s41419-019-1663-5. View

Battistella C, Klok H . Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. Biomacromolecules. 2017; 18(6):1855-1865. DOI: 10.1021/acs.biomac.7b00291. View

Russo A, Li P, Strong V . Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol. 2017; 115(5):603-614. DOI: 10.1002/jso.24517. View

Fu Y, Wei J, Dai X, Ye Y . Increased NDRG1 expression attenuate trophoblast invasion through ERK/MMP-9 pathway in preeclampsia. Placenta. 2017; 51:76-81. DOI: 10.1016/j.placenta.2017.01.126. View

10.

Luo Y, Zha L, Luo L, Chen X, Zhang Q, Gao C . [6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway. Phytother Res. 2019; 33(5):1353-1362. DOI: 10.1002/ptr.6325. View

11.

Ciesielski M, Kruszewski W, Walczak J, Szajewski M, Szefel J, Wydra J . Analysis of postoperative morbidity and mortality following surgery for gastric cancer. Surgeon volume as the most significant prognostic factor. Prz Gastroenterol. 2017; 12(3):215-221. PMC: 5672710. DOI: 10.5114/pg.2017.70475. View

12.

Willmer T, Peres J, Mowla S, Abrahams A, Prince S . The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2. Cell Cycle. 2015; 14(19):3173-83. PMC: 4825571. DOI: 10.1080/15384101.2015.1080398. View

13.

Wei X, Gao M, Ahmed Y, Gao M, Liu W, Zhang Y . MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Oncol Lett. 2019; 18(2):1607-1616. PMC: 6607034. DOI: 10.3892/ol.2019.10496. View

14.

Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T . Medical management of gastric cancer: a 2017 update. Cancer Med. 2017; 7(1):123-133. PMC: 5773977. DOI: 10.1002/cam4.1274. View

15.

Liu F, Yin R, Chen X, Chen W, Qian Y, Zhao Y . Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 2019; 114:108605. DOI: 10.1016/j.biopha.2019.108605. View

16.

Tian S, Wang X, Proud C . Oncogenic MNK signalling regulates the metastasis suppressor NDRG1. Oncotarget. 2017; 8(28):46121-46135. PMC: 5542254. DOI: 10.18632/oncotarget.17555. View

17.

Wen Q, Luo K, Huang H, Liao W, Yang H . Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway. Med Sci Monit. 2019; 25:8025-8033. PMC: 6827329. DOI: 10.12659/MSM.911697. View

18.

Song Z, Wu Y, Yang J, Yang D, Fang X . Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017; 39(7):1010428317714626. DOI: 10.1177/1010428317714626. View

19.

Yao Y, Yang X, Sun L, Sun S, Huang X, Zhou D . Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer. EBioMedicine. 2019; 41:256-267. PMC: 6441949. DOI: 10.1016/j.ebiom.2019.01.066. View

20.

Farah C, Sossin W . The role of C2 domains in PKC signaling. Adv Exp Med Biol. 2012; 740:663-83. DOI: 10.1007/978-94-007-2888-2_29. View